ConductScience.org, home

Paper36765658

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.

Long Z and 10 others. Cancers (Basel), 2023. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. Papers, record 36765658. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765658

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.39
iCite
Revised in PubMed
2023-02-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Long ZZuoyaohttps://orcid.org/0000-0002-8957-6166
2Lu YYajie
3Li MMinghui
4Fu ZZhanli
5Akbar YYunus
6Li JJing
7Chen GGuojing
8Zhang HMHong-Meihttps://orcid.org/0000-0002-3991-3750
9Wang QQi
10Xiang LLiangbi
11Wang ZZhen

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
228656259Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Oncol Rep2017https://conductscience.org/library/papers/28656259PubMed
320217247Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence.Ann Surg Oncol2010https://conductscience.org/library/papers/20217247PubMed
428660302Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Angiogenesis2017https://conductscience.org/library/papers/28660302PubMed
511533692Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.Nat Med2001https://conductscience.org/library/papers/11533692PubMed
64332371Isolation of a tumor factor responsible for angiogenesis.J Exp Med1971https://conductscience.org/library/papers/4332371PubMed
732110053Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.Onco Targets Ther2020https://conductscience.org/library/papers/32110053PubMed
818572972Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.Am J Clin Dermatol2008https://conductscience.org/library/papers/18572972PubMed
922648518Local recurrence of localized soft tissue sarcoma: a new look at old predictors.Cancer2012https://conductscience.org/library/papers/22648518PubMed
1034281731Impact of histological subtype on radiological and pathological response after neoadjuvant radiotherapy in soft tissue sarcoma.Eur J Surg Oncol2021https://conductscience.org/library/papers/34281731PubMed
1135912272Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.Front Oncol2022https://conductscience.org/library/papers/35912272PubMed
1221746804Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.Ann Oncol2012https://conductscience.org/library/papers/21746804PubMed
1328499583
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Lancet Oncol2017https://conductscience.org/library/papers/28499583PubMed
1424378391WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition.Pathology2014https://conductscience.org/library/papers/24378391PubMed
1526014294
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol2015https://conductscience.org/library/papers/26014294PubMed
1615175435Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med2004https://conductscience.org/library/papers/15175435PubMed
1732181596Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.Cancer Med2020https://conductscience.org/library/papers/32181596PubMed
1830231931Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.J Hematol Oncol2018https://conductscience.org/library/papers/30231931PubMed
1933546021Impact of surgical margin on survival in extremity soft tissue sarcoma: A systematic review and meta-analysis.Medicine (Baltimore)2021https://conductscience.org/library/papers/33546021PubMed
2029454091Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.Gene2018https://conductscience.org/library/papers/29454091PubMed

See all 33 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42614758Primary leiomyosarcoma of the lumbar soft tissue treated with multimodal therapy, including anlotinib: A case report.Oncol Lett2026https://conductscience.org/library/papers/42614758PubMed
42205857
Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis.
Ther Adv Med Oncol2026https://conductscience.org/library/papers/42205857PubMed
41128656First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial.Clin Cancer Res2026https://conductscience.org/library/papers/41128656PubMed
39618078The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient-Derived Xenografts and Next-Generation Sequencing.Cancer Med2024https://conductscience.org/library/papers/39618078PubMed
38967496Safety and efficacy of fruquintinib-based therapy in patients with advanced or metastatic sarcoma.Cancer Med2024https://conductscience.org/library/papers/38967496PubMed
38515149CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.Mol Cancer2024https://conductscience.org/library/papers/38515149PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36765658

GET https://conductscience.org/api/papers/v1/36765658/references?page=2